Modus Therapeutics Holding AB (publ) (MODTX.ST)
SEK 1.16
(0.43%)
SEK 1.16
(0.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2000.00 SEK | 9.4% |
| 2022 | -18 Million SEK | 12.97% |
| 2021 | -20.69 Million SEK | -243.8% |
| 2020 | -6.01 Million SEK | 86.19% |
| 2019 | -43.57 Million SEK | 11.23% |
| 2018 | - SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.8 Million SEK | 0.0% |
| 2024 Q1 | -3.18 Million SEK | 0.0% |
| 2023 Q1 | -5.8 Million SEK | 36.32% |
| 2023 FY | - SEK | 9.4% |
| 2023 Q4 | -3.77 Million SEK | -53.66% |
| 2023 Q3 | -2.45 Million SEK | 43.73% |
| 2023 Q2 | -4.36 Million SEK | 24.85% |
| 2022 Q3 | -2.82 Million SEK | 5.45% |
| 2022 Q1 | -3.06 Million SEK | 75.06% |
| 2022 Q2 | -2.99 Million SEK | 2.38% |
| 2022 FY | - SEK | 12.97% |
| 2022 Q4 | -9.12 Million SEK | -222.41% |
| 2021 FY | - SEK | -243.8% |
| 2021 Q1 | -1.42 Million SEK | -40.28% |
| 2021 Q4 | -12.28 Million SEK | -176.65% |
| 2021 Q3 | -4.44 Million SEK | -75.43% |
| 2021 Q2 | -2.53 Million SEK | -77.31% |
| 2020 Q4 | -1.01 Million SEK | -46.26% |
| 2020 Q1 | -2.6 Million SEK | 0.0% |
| 2020 FY | - SEK | 86.19% |
| 2020 Q3 | -696 Thousand SEK | -23300.0% |
| 2020 Q2 | 3000.00 SEK | 100.12% |
| 2019 FY | - SEK | 11.23% |
| 2018 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 100.005% |
| Amniotics AB (publ) | -27.14 Million SEK | 100.007% |
| BioArctic AB (publ) | 275.38 Million SEK | 99.999% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 100.001% |
| Camurus AB (publ) | 562.54 Million SEK | 100.0% |
| Cantargia AB (publ) | -284.31 Million SEK | 100.001% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 100.01% |
| CombiGene AB (publ) | -35.33 Million SEK | 100.006% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 100.001% |
| Genovis AB (publ.) | 64.57 Million SEK | 99.997% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 100.002% |
| Mendus AB (publ) | -97.84 Million SEK | 100.002% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 100.005% |
| Intervacc AB (publ) | -68.98 Million SEK | 100.003% |
| Kancera AB (publ) | -61.88 Million SEK | 100.003% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 100.007% |
| LIDDS AB (publ) | -39.67 Million SEK | 100.005% |
| Lipum AB (publ) | -37.11 Million SEK | 100.005% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 100.017% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 99.994% |
| NextCell Pharma AB | -40.98 Million SEK | 100.005% |
| OncoZenge AB (publ) | 7.26 Million SEK | 99.972% |
| Saniona AB (publ) | -69.69 Million SEK | 100.003% |
| Simris Alg AB (publ) | -22.36 Million SEK | 100.009% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 100.001% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 100.001% |
| Xintela AB (publ) | -53.47 Million SEK | 100.004% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 100.001% |
| Ziccum AB (publ) | -20.34 Million SEK | 100.01% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 100.014% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 100.012% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 100.001% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 100.096% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 100.015% |
| Corline Biomedical AB | -1.69 Million SEK | 100.118% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 100.001% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 100.004% |
| Aptahem AB (publ) | -10 Million SEK | 100.02% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 99.983% |
| Fluicell AB (publ) | -25.91 Million SEK | 100.008% |
| Biovica International AB (publ) | -119.5 Million SEK | 100.002% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 100.005% |
| AcouSort AB (publ) | -16.7 Million SEK | 100.012% |
| Abliva AB (publ) | -93.6 Million SEK | 100.002% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 100.001% |
| 2cureX AB (publ) | -35.13 Million SEK | 100.006% |
| I-Tech AB | 30.34 Million SEK | 99.993% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 100.0% |
| Cyxone AB (publ) | -20.41 Million SEK | 100.01% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 100.002% |
| Biosergen AB | 228 Thousand SEK | 99.123% |
| Nanologica AB (publ) | -62.11 Million SEK | 100.003% |
| SynAct Pharma AB | -222.7 Million SEK | 100.001% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 100.005% |
| BioInvent International AB (publ) | -312.7 Million SEK | 100.001% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 99.354% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 95.238% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 100.001% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 100.023% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 100.002% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 100.017% |